Amphastar Pharmaceuticals Inc (AMPH)
45.46
+0.91
(+2.04%)
USD |
NASDAQ |
Nov 22, 16:00
45.43
-0.03
(-0.07%)
After-Hours: 20:00
Amphastar Pharmaceuticals Net Income (Quarterly): 40.43M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 40.43M |
| June 30, 2024 | 37.95M |
| March 31, 2024 | 43.18M |
| December 31, 2023 | 36.17M |
| September 30, 2023 | 49.22M |
| June 30, 2023 | 26.12M |
| March 31, 2023 | 26.03M |
| December 31, 2022 | 33.91M |
| September 30, 2022 | 15.87M |
| June 30, 2022 | 17.35M |
| March 31, 2022 | 24.25M |
| December 31, 2021 | 19.76M |
| September 30, 2021 | 29.55M |
| June 30, 2021 | 7.767M |
| March 31, 2021 | 5.041M |
| December 31, 2020 | -6.273M |
| September 30, 2020 | 3.919M |
| June 30, 2020 | -0.192M |
| March 31, 2020 | 3.949M |
| December 31, 2019 | -1.026M |
| September 30, 2019 | 1.31M |
| June 30, 2019 | 47.79M |
| March 31, 2019 | 0.868M |
| December 31, 2018 | 1.867M |
| Date | Value |
|---|---|
| September 30, 2018 | 2.389M |
| June 30, 2018 | -2.853M |
| March 31, 2018 | -7.141M |
| December 31, 2017 | 0.787M |
| September 30, 2017 | 0.099M |
| June 30, 2017 | 1.972M |
| March 31, 2017 | 0.893M |
| December 31, 2016 | -3.454M |
| September 30, 2016 | 3.89M |
| June 30, 2016 | 6.895M |
| March 31, 2016 | 2.489M |
| December 31, 2015 | 7.533M |
| September 30, 2015 | -3.008M |
| June 30, 2015 | -6.647M |
| March 31, 2015 | -0.665M |
| December 31, 2014 | -2.521M |
| September 30, 2014 | -5.379M |
| June 30, 2014 | -1.18M |
| March 31, 2014 | -1.619M |
| December 31, 2013 | 1.829M |
| September 30, 2013 | -0.159M |
| June 30, 2013 | 7.81M |
| March 31, 2013 | 2.382M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-6.273M
Minimum
Dec 2020
49.22M
Maximum
Sep 2023
20.65M
Average
22.01M
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly and Co | 970.30M |
| BridgeBio Pharma Inc | -162.04M |
| NovaBay Pharmaceuticals Inc | -1.212M |
| Palatin Technologies Inc | -7.824M |
| iBio Inc | -3.989M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 191.21M |
| Total Expenses (Quarterly) | 134.17M |
| EPS Diluted (Quarterly) | 0.78 |
| Enterprise Value | 2.532B |
| Gross Profit Margin (Quarterly) | 53.31% |
| Profit Margin (Quarterly) | 21.14% |
| Earnings Yield | 6.60% |
| Operating Earnings Yield | 8.98% |
| Normalized Earnings Yield | 6.599 |